Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $1.38B.
ENTERPRISE VALUE (EV)
$1.38B
Inhibrx Biosciences Inc.
Market Cap
$1.40B
Enterprise Value (EV)
$1.38B
Market Cap
$1.38B
Enterprise Value (EV)
$1.14B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.40B | $1.38B |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | $1.28B |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | $1.14B |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | $1.57B |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.36B | $1.35B |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | $1.33B |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | $1.33B |
| Braveheart Bio, Inc. (BRVE)vs › | $1.48B | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | $1.17B |
| GH Research PLC (GHRS)vs › | $1.51B | $1.16B |
Market Cap
$1.40B
Total Debt
$102.89M
Cash
$124.22M
Enterprise Value
$1.38B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
